Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma

• Main Authors: Theresa Stork, Rebecca Boemans, Jendrik Hardes, Arne Streitbürger, Uta Dirksen, Christoph Pöttgen, Hans-Ulrich Schildhaus, Sebastian Bauer, Stéphane Collaud, Clemens Aigner
• Format: Article
• Language: English
• Published: BMC 2021-04-01
• Series: BMC Cancer
• Subjects: Pulmonary metastasectomy; Bone sarcoma; Lung metastases
• Online Access: https://doi.org/10.1186/s12885-021-08073-3

Abstract Background Pulmonary metastasectomy (PM) is an established treatment for selected patients with metastatic sarcomas. The aim of this study was to examine our institutional experience and evaluate factors predicting outcome. Methods We retrospectively reviewed all patients undergoing PM for bone sarcoma in our center from 2001 to 2019. Survival was calculated from the date of PM. Impact on survival of clinical parameters was assessed. Results Thirty-eight patients (27 males, 71%) were included. Histology was osteosarcoma (n = 20, 53%), Ewing sarcoma (n = 13, 34%) and chondrosarcoma (n = 5, 13%). Twelve patients (31.5%) had synchronous metastases, all received chemotherapy before PM. Median number of metastases was 3 (1 to 29). Twenty (53%) patients had mediastinal lymph node sampling. One patient had positive lymph nodes. Ninety-day mortality was 0%. Three and 5-year PFS were 24.5 and 21%, respectively. Three and 5-year OS were 64.5 and 38.5%, respectively. More than three metastases and progression under chemotherapy were significant independent predictors for OS. Conclusion PM is a safe procedure and encouraging long-term outcome can be achieved. Patients with progression of pulmonary metastases under chemotherapy as well as patients with more than three metastases had significantly worse OS.